These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. Sormani MP; Muraro PA; Saccardi R; Mancardi G Mult Scler; 2017 Feb; 23(2):201-204. PubMed ID: 27207454 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis. Ge F; Lin H; Li Z; Chang T Neurol Sci; 2019 Mar; 40(3):479-487. PubMed ID: 30535563 [TBL] [Abstract][Full Text] [Related]
4. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient. Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119 [TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives. Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670 [TBL] [Abstract][Full Text] [Related]
6. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994 [TBL] [Abstract][Full Text] [Related]
13. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R; JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268 [TBL] [Abstract][Full Text] [Related]
14. Immunoablative therapy followed by autologous hematopoietic stem cell transplantation as the first-line disease-modifying therapy in patients with multiple sclerosis. Lachnit M; Revendova KZ; Hradilek P; Bunganic R; Koristek Z; Jelinek T; Skutova M; Piza R; Volny O; Hajek R; Bar M Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2024 Mar; 168(1):50-54. PubMed ID: 37337857 [TBL] [Abstract][Full Text] [Related]
15. Autologous hematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: Danish nation-wide experience. Jespersen F; Petersen SL; Andersen P; Sellebjerg F; Magyari M; Sørensen PS; Blinkenberg M Mult Scler Relat Disord; 2023 Aug; 76():104829. PubMed ID: 37364374 [TBL] [Abstract][Full Text] [Related]
16. Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation. Daumer M; Griffith LM; Meister W; Nash RA; Wolinsky JS Mult Scler; 2006 Apr; 12(2):174-9. PubMed ID: 16629420 [TBL] [Abstract][Full Text] [Related]
17. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis. Mariottini A; Filippini S; Innocenti C; Forci B; Mechi C; Barilaro A; Fani A; Carlucci G; Saccardi R; Massacesi L; Repice AM Mult Scler; 2021 Jan; 27(1):61-70. PubMed ID: 32008439 [TBL] [Abstract][Full Text] [Related]
18. Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how. Szczechowski L; Śmiłowski M; Helbig G; Krawczyk-Kuliś M; Kyrcz-Krzemień S Int J Neurosci; 2016 Oct; 126(10):867-71. PubMed ID: 26577419 [TBL] [Abstract][Full Text] [Related]
19. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis]. Saiz A; Blanco Y; Berenguer J; Gómez-Choco M; Carreras E; Arbizu T; Graus F Neurologia; 2008 Sep; 23(7):405-7. PubMed ID: 18726717 [TBL] [Abstract][Full Text] [Related]
20. Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis. Gottschlich KN; Zolic-Karlsson Z; Aas E; Kvistad SAS; Bø L; Torkildsen Ø; Lehmann AK Mult Scler Relat Disord; 2024 Apr; 84():105507. PubMed ID: 38412758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]